Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

H3K9 dimethylation safeguards cancer cells against activation of the interferon pathway

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Mutations in BCOR, a co-repressor of CRX/OTX2, are associated with early-onset retinal degeneration

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Deep learning-based integration of genetics with registry data for stratification of schizophrenia and depression

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Systematic dissection of transcriptional regulatory networks by genome-scale and single-cell CRISPR screens

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Tumor repolarization by an advanced liposomal drug delivery system provides a potent new approach for chemo-immunotherapy

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Progression of the pluripotent epiblast depends upon the NMD Factor UPF2

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Engineering human mini-bones for the standardized modeling of healthy hematopoiesis, leukemia, and solid tumor metastasis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Dynamic intron retention modulates gene expression in the monocytic differentiation pathway

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Activation of interferon genes constitutes an important anticancer pathway able to restrict proliferation of cancer cells. Here, we demonstrate that the H3K9me3 histone methyltransferase (HMT) suppressor of variegation 3-9 homolog 1 (SUV39H1) is required for the proliferation of acute myeloid leukemia (AML) and find that its loss leads to activation of the interferon pathway. Mechanistically, we show that this occurs via destabilization of a complex composed of SUV39H1 and the two H3K9me2 HMTs, G9A and GLP. Indeed, loss of H3K9me2 correlated with the activation of key interferon pathway genes, and interference with the activities of G9A/GLP largely phenocopied loss of SUV39H1. Last, we demonstrate that inhibition of G9A/GLP synergized with DNA demethylating agents and that SUV39H1 constitutes a potential biomarker for the response to hypomethylation treatment. Collectively, we uncovered a clinically relevant role for H3K9me2 in safeguarding cancer cells against activation of the interferon pathway.

Original languageEnglish
Article numberabf8627
JournalScience Advances
Volume8
Issue number11
Pages (from-to)eabf8627
DOIs
Publication statusPublished - 18 Mar 2022

ID: 76236453